Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 2/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 8/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274292 | 0.93 | PREP (0.47) | CACNA1HCACNA1BNPC1GAARAB9A | |
| SCHEMBL3274249 | 0.93 | CACNA1H (0.49) | CACNA1HCACNA1BNPC1GAARAB9A | |
| SCHEMBL3278221 | 0.92 | NPC1 (0.47) | CACNA1HCACNA1BNPC1GAARAB9A | |
| SCHEMBL15104131 | 0.86 | NPC1 (0.49) | CACNA1HCACNA1BNPC1GAARAB9A | |
| SCHEMBL15104149 | 0.85 | CACNA1H (0.47) | CACNA1HCACNA1BNPC1GAARAB9A | |
| SCHEMBL15103825 | 0.85 | CCR2 (0.45) | CACNA1HCACNA1BNPC1GAARAB9A | |
| SCHEMBL15103781 | 0.84 | CACNA1H (0.47) | CACNA1HCACNA1BNPC1GAARAB9A | |
| SCHEMBL15103945 | 0.84 | NPC1 (0.47) | CACNA1HCACNA1BNPC1GAARAB9A | |
| SCHEMBL15104222 | 0.84 | SMN1; SMN2 (0.50) | CACNA1HCACNA1BNPC1GAARAB9A | |
| SCHEMBL15103922 | 0.84 | SMN1; SMN2 (0.48) | CACNA1HCACNA1BNPC1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076491-B1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-07-17 | — | — | EP | disclosed |
| US-8481527-B2 | Benzamide derivatives as bradykinin antagonists | RICHTER GEDEON NYRT. (HU) | 2013-07-09 | — | — | US | disclosed |
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | CACNA1H 997/4885CACNA1B 915/4885NPC1 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.